



New ideas, better medicine

A new approach.

ChemoCentryx is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel medicines that selectively block key chemokine or chemoattractant receptors to address high unmet medical needs in inflammatory and autoimmune diseases.

We are engineering biotechnology that harnesses the power of the chemoattractant system. Our mission is to create better-targeted and more effective medicines.

A better approach.

Our passion for science motivates us. And we're devoted to providing profound improvements to individuals challenged by serious disease. We already have a broad portfolio of therapeutics in areas including orphan and rare diseases, chronic kidney disease, immuno-oncology, and inflammatory and autoimmune diseases.

We are developing a better way to treat disease

www.advocateclinicaltrial.com

www.c3gstudy.com

www.auroraforhs.com

www.fsgslumina.com



850 Maude Avenue
Mountain View, CA 94043
(650) 210-2900

info@chemocentryx.com

www.chemocentryx.com

We are developing tomorrow's standard of care

At ChemoCentryx, we are developing a broad portfolio of new medicines using a novel approach to provide patients with safe, convenient, and more effective therapies.

Therapeutic Area	Drug/Target	Indication	Preclinical	Phase I	Phase II	Phase III
Complement Inhibition in Orphan Diseases	Avacopan (formerly CCX168)/ C5aR	ANCA-ASSOCIATED VASCULITIS*				
		C3 GLOMERULOPATHY				
		HIDRADENITIS SUPPURATIVA				
Chronic and Other Rare Kidney Diseases	CCX140/ CCR2	ORPHAN KIDNEY DISEASE - FOCAL SEGMENTAL GLOMERULOSCLEROSIS				
		DIABETIC KIDNEY DISEASE, SUCCESSFULLY COMPLETED PHASE II				
Other Inflammatory and Autoimmune Diseases	CCX507/ CCR9	IBD: ULCERATIVE COLITIS				
	CCX587/ CCR6	TH17 DRIVEN DISEASES, e.g. PUSTULAR PSORIASIS				
Immuno-Oncology	CCX872/ CCR2	ADVANCED PANCREATIC CANCER				
	CCR1/ CXCR2	OTHER ONCOLOGY TARGETS				

*Phase III ADVOCATE trial is fully enrolled. Top-line data are expected in Q4 2019.

Discover how we are developing a better way to treat disease at chemocentryx.com